ライフサイエンスコーパス: injection site reaction

1 tinued drug due to an adverse event (grade 2 injection site reaction).

2 ubcutaneous group (mainly grade 1 or 2 local injection-site reactions).

3 The most common adverse event was injection site reaction.

4 thma, upper respiratory tract infection, and injection site reaction.

5 1 to 2 toxicities including rash, fever, and injection site reaction.

6 han expected frequency and severity of local injection site reactions.

7 nemia, fatigue, thrombocytopenia, fever, and injection site reactions.

8 ommon treatment-emergent adverse events were injection site reactions.

9 Five patients reported transient injection site reactions.

10 s promising but invasive and associated with injection site reactions.

11 erixafor were gastrointestinal disorders and injection site reactions.

12 ociated adverse events were GI disorders and injection site reactions.

13 re mild or moderate, and 94% of patients had injection site reactions.

14 lerated; the most common adverse events were injection site reactions.

15 common adverse events were mild to moderate injection site reactions.

16 were rashes, possible vaccine failures, and injection site reactions.

17 st common grade 3 toxicities were related to injection-site reactions.

18 The most common adverse events were mild injection-site reactions.

19 ons with IONIS-APO(a)Rx were associated with injection-site reactions.

20 IONIS-APO(a)-LRx was associated with no injection-site reactions.

21 A85A was associated with expected mild local injection-site reactions.

22 ents (AEs) experienced by subjects were mild injection-site reactions.

23 among patients who received bococizumab was injection-site reaction (12.7 per 100 person-years).

24 iratory tract infections (33-41% vs 35%) and injection-site reactions (13-26% vs 13%).

25 events in drisapersen-treated patients were injection-site reactions (14 patients given continuous d

26 Toxicity was mild, with injection site reactions (20%) and minor infections (10%

27 t common adverse events in the GA group were injection site reactions (35.5% with GA vs 5.0% with pla

28 with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4%

29 b vs 13 [6%] patients receiving placebo) and injection site reactions (60 [16%] vs eight [4%]) occurr

30 Patients in the anakinra group had more injection site reactions (68% [17 of 25] vs. 4% [1 of 25

31 lacebo group vs 47% in the dupilumab group), injection site reactions (7% vs 40%, respectively), and

32 Common adverse events included injection site reactions (78% with mipomersen, 31% with

33 ntly more often in the etanercept group were injection-site reactions, accidental injuries, and upper

34 Injection site reactions after Tdap immunization were re

35 tidergic drugs associated with allergic-type injection-site reactions also activate Mrgprb2 and MRGPR

36 .4%] and 378 [9.5%; 95% CI, 8.6%-10.5%] with injection site reactions and 66 [1.7%; 95% CI, 1.3%-2.1%

37 se events were negligible and included minor injection site reactions and bone pain.

38 Injection site reactions and gastrointestinal symptoms w

39 Adverse events included injection site reactions and influenza-like symptoms.

40 ving biologic agents, most frequently citing injection site reactions and lack of efficacy as reasons

41 Injection site reactions and transient elevations of liv

42 Mild-to-moderate injection-site reactions and bone pain were more common

43 Injection-site reactions and conjunctivitis were more co

44 most frequently reported adverse events were injection-site reactions and dizziness, which were self-

45 Common adverse effects were injection-site reactions and fatigue.

46 rticipants in the albiglutide group had more injection-site reactions and fewer gastrointestinal even

47 The most common adverse events were mild injection-site reactions and mild upper respiratory trac

48 y vaccinated participants reported solicited injection site reactions, and 50 (78%) of 64 intradermal

49 were assessed by monitoring adverse events, injection site reactions, and laboratory test results.

50 pt alone, 3.7-7.4% for combination therapy), injection-site reactions, and neutropenia was increased

51 events associated with etanercept were mild injection-site reactions, and no patient withdrew from t

52 hvCNTF, in a dose-related fashion, with mild injection site reactions as the most frequently reported

53 ommon adverse events including headache, new injection site reaction, asthenia, abdominal pain, Crohn

54 ally well tolerated and associated with more injection-site reactions, but less mucositis than placeb

55 ts, as follows, appeared to be dose related: injection site reactions, cough, asthenia, nausea, anore

56 both groups, and mild-to-moderate transient injection-site reactions (eg, erythema, pruritus) were t

57 rall frequency in the PIXY321 group included injection-site reactions, fever, chills, abdominal pain,

58 reported symptoms and signs included fever, injection site reactions, fussiness, rashes, and urticar

59 uently reported type of adverse event was an injection site reaction in 445 patients (50.2%), followe

60 n the occurrence of significantly more local injection site reactions in patients treated with SC ada

61 ich was mainly because of a higher number of injection site reactions in the anakinra group.

62 We noted grade 1-2 injection-site reactions in 36 (33%) of 110 patients in

63 nes than with placebo; these events included injection-site reactions (in 28.5% of the patients in th

64 s associated with peginterferon beta-1a were injection site reactions, influenza-like symptoms, pyrex

65 Detailed clinical (including injection site reaction (ISR) grading), plasma pharmacok

66 Injection site reactions (ISRs) were the most common adv

67 igh incidence of transient, mild-to-moderate injection-site reactions, long-acting cabotegravir was w

68 SC injection site reactions (mostly mild) occurred in 19 SC

69 lecystitis (n=2), phototoxic skin (n=5), and injection site reactions (n=7).

70 Injection-site reactions, nasopharyngitis, nausea, and h

71 ents should be aware that self-limited local injection site reactions occur more frequently following

72 Injection site reactions occurred in 20 of 106 patients

73 Injection site reactions occurred in 3.8% of patients re

74 Few injection-site reactions occurred (3%).

75 Injection-site reactions occurred in 5% of the patients

76 Injection-site reactions occurred in more patients given

77 Injection-site reactions occurred in most patients, but

78 Mild injection-site reactions occurred more frequently among

79 Adverse events were mostly injection site reactions occurring after QbG10 administr

80 d their first vaccinations to report a local injection site reaction of at least 10.2 cm (4 in) in di

81 the participants in the 2 studies developed injection site reactions or paresthesiae.

82 eater median number of docetaxel cycles) and injection-site reactions (P<.001).

83 requently reported adverse events were local injection site reactions such as injection site swelling

84 associated with a higher frequency of local injection site reactions than was the use of needle and

85 a group, vaccine recipients experienced more injection-site reactions than did placebo recipients; ho

86 Injection-site reactions to the drug were common.

87 ith the exception of mild-to-moderate XR-NTX injection site reactions, treatment-emergent adverse eve

88 Injection site reaction was the most frequently noted ad

89 Minor injection site reactions were common and similar in freq

90 HZ vaccine was well tolerated; injection site reactions were generally mild.

91 Rates of injection site reactions were low.

92 Injection site reactions were mild or moderate.

93 Systemic and injection site reactions were mild, transient, and simil

94 Mild injection site reactions were more common in the Cervari

95 Injection site reactions were more frequent in the intra

96 Injection site reactions were more frequent with rilonac

97 Injection site reactions were recorded in nine (9%) pati

98 Late-onset injection site reactions were seen in all ACV groups.

99 Mild injection site reactions were the most common adverse ev

100 a multi-agent pre-medication regimen; local injection site reactions were the most commonly seen adv

101 Injection site reactions were the most frequently report

102 Injection-site reactions were mild (3648 [84%] of 4360 i

103 Injection-site reactions were more common in the bocociz

104 Injection-site reactions were the most commonly reported

105 verity of reported adverse events, including injection site reactions, were similar in the generic dr

106 T-1249 was generally well tolerated; injection site reactions, which were generally mild, wer

107 frequencies in all 4 treatment groups except injection site reactions, which were more common in adal

108 eurocognitive events), with the exception of injection-site reactions, which were more common with ev

109 The most frequent adverse event was injection-site reactions, which were reported in 62% of

110 The most common adverse event was injection-site reaction with one patient in the group of

111 versus control, except for a higher rate of injection-site reactions with alirocumab.

112 Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse event